Résumé
<p><b>OBJECTIVE</b>To investigate the regulatory effects of fenofibrate on TNF-alpha-induced CD40 expression and matrix metalloproteinase (MMP) activity in human vascular endothelial cells (HUVECs).</p><p><b>METHODS</b>Quantitative RT-PCR and flow cytometry were employed to evaluate the effect of fenofibrate on TNF-alpha-induced CD40 mRNA and cell surface CD40 expression in HUVECs, and gelatin zymography was used to determine the effect of fenofibrate on the gelatinolytic activities of MMP-2 and MMP-9 in TNF-alpha-stimulated HUVECs.</p><p><b>RESULTS</b>Fenofibrate at the concentrations of 5x10(-5), 1x10(-4) and 2x10(-4) mol/L significantly reduced TNF-alpha-induced increment of CD40 mRNA and cell surface CD40 expressions (P<0.01), with the maximal inhibition achieved at the concentration of 1x10(-4) mol/L. Fenofibrate at 2x10(-4) mol/L did not further decrease CD40 expression induced by TNF-alpha. Fenofibrate significantly inhibited the stimulatory effect of TNF-alpha on MMP-2 and MMP-9 activities in HUVECs.</p><p><b>CONCLUSION</b>Fenofibrate reduces TNF-alpha-induced increment of CD40 expression and MMP-2 and MMP-9 activities in HUVECs.</p>
Sujets)
Humains , Antigènes CD40 , Génétique , Cellules cultivées , Relation dose-effet des médicaments , Cellules endothéliales , Biologie cellulaire , Métabolisme , Fénofibrate , Pharmacologie , Cytométrie en flux , Matrix metalloproteinase 2 , Métabolisme , Matrix metalloproteinase 9 , Métabolisme , Matrix metalloproteinases , Métabolisme , ARN messager , Génétique , RT-PCR , Facteur de nécrose tumorale alpha , Pharmacologie , Veines ombilicales , Biologie cellulaireRésumé
<p><b>OBJECTIVE</b>To investigate the effects of ligustrazine on nitric oxide (NO), malonaldehyde (MDA) production, release of intracellular lactate dehydrogenase (LDH) and membrane fluidity of the injured human umbilical vein vascular endothelial cell line (ECV-304) with hypoxia and lack of glucose.</p><p><b>METHOD</b>The experiments were performed in culture of ECV-304 injured with hypoxia and lack of glucose in vitro. The released LDH of ECV-304 was measured with automatic biochemistry analyse. NO content of ECV-304 was monitored with colorimetry. Lipid peroxidation of ECV-304 was monitored as MDA with a fluorometric assay. The membrane fluidity of ECV-304 was measured with the fluorescence polarization method.</p><p><b>RESULT</b>After culture ECV-304 in hypoxia and lack of glucose for 24 h, the LDH release, MDA production and the membrane fluidity increased significantly and NO level was decreased. Preincubation of ECV-304 with ligustrazine for 24 h reduced LDH release, MDA production, membrane fluidity increasing and increased the level of NO in ECV-304 due to hypoxia and lack of glucose.</p><p><b>CONCLUSION</b>Ligustrazine has protective effect on injury of ECV-304 induced by hypoxia and lack of glucose.</p>
Sujets)
Humains , Hypoxie cellulaire , Lignée cellulaire , Membrane cellulaire , Cellules endothéliales , Métabolisme , Hypoglycémie , Métabolisme , Anatomopathologie , L-Lactate dehydrogenase , Métabolisme , Ligusticum , Chimie , Malonaldéhyde , Métabolisme , Fluidité membranaire , Monoxyde d'azote , Métabolisme , Plantes médicinales , Chimie , Agents protecteurs , Pharmacologie , Pyrazines , PharmacologieRésumé
This paper describes a type of blood pressure monitor we have developed using 8031 chip microprocessor based on oscillometric method and the designs of hardware and software. Comparing the measurement results of oscillometric method with that of direct invasive measurement method, we find that the monitor is very useful in clinical applications. Finally in the paper, some improvements that can be made in the monitor are proposed.